Bioinformatics: How it is being used to identify bacterial vaccine candidates

Expert Review of Vaccines

Volumn 2, Issue 3, 2003, Pages 417-436

  Zagursky, Robert J ^a   Olmsted, Stephen B ^a   Russell, David P ^b   Wooters, Joe L ^a  

^a PFIZER INC   (United States)

^b LPA Systems Inc   (United States)

Author keywords

Bacteria; Bioinformatics; Genomics; Microarray; Proteomics; Transcriptomics; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL VACCINE; CHOLERA VACCINE; DIPHTHERIA VACCINE; INFLUENZA VACCINE; LYME DISEASE VACCINE; MENINGITIS VACCINE; PERTUSSIS VACCINE; STAPHYLOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID;

ANALYTIC METHOD; BACILLUS ANTHRACIS; BACTERIUM IDENTIFICATION; BIOINFORMATICS; BORDETELLA PERTUSSIS; BORRELIA BURGDORFERI; CLOSTRIDIUM TETANI; CORYNEBACTERIUM DIPHTHERIAE; DATA ANALYSIS; DRUG RESEARCH; DRUG SPECIFICITY; GENE SEQUENCE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE TYPE B; INFORMATION PROCESSING; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VACCINE PRODUCTION; VIBRIO CHOLERAE;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BASE SEQUENCE; COMPUTATIONAL BIOLOGY; DRUG DESIGN; GENE EXPRESSION PROFILING; GENES, BACTERIAL; GENOMICS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; OPEN READING FRAMES; PROTEOMICS; RESEARCH; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TRANSCRIPTION, GENETIC;

EID: 0037833535     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.3.417     Document Type: Review

References (187)

1. Fauci AS. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32(5), 675-685 (2001).
2. World Health Report, World Health Organization Report on Infectious Diseases: Removing Obstacles to Healthy Development, Geneva, World Health Organization, 68 (1999).
3. Benton D. Bioinformatics - principles and potential of a new multidisciplinary tool. Trends Biotechnol. 14(8), 261-272 (1996).
4. McKusick VA, Ruddle FH. Toward a complete map of the human genome. Genomics 1(2), 103-106 (1987).
5. Wasinger VC, Cordwell SJ, Cerpa-Poljak A et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16(7), 1090-1094 (1995).
6. Velculescu VE, Zhang L, Zhou W et al. Characterization of the yeast transcriptome. Cell 88(2), 243-251 (1997).
7. Klysik J. Concept of immunomics: a new frontier in the battle for gene function? Acta Biotheor. 49(3), 191-202 (2001).
8. Hanash SM, Bobek MR, Rickman DS et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2(1), 69-75 (2002).
9. Gabius HJ, Andre S, Kaltner H, Siebert HC. The sugar code: functional lectinomics. Biochim. Biophys. Acta Gen. Subjects 1572(2-3), 165-177 (2002).
10. Cooper DNW. Galectinomics: finding themes in complexity. Biochim. Biophys. Acta Gen. Subjects 1572(2-3), 209-231 (2002).
11. Tenenbaum SA, Lager PJ, Carson CC, Keene JD. Ribonomics: idendfying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods 26(2), 191-198 (2002).
12. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17-19), 2688-2691 (2001).
13. Kellam P. Post-genomic virology: the impact of bioinformatics, microarrays and proteomics on investigating host and pathogen interactions. Rev. Med. Virol. 11(5), 313-329 (2001).
14. Moxon R, Rappuoli R. Bacterial pathogen genomics and vaccines. Br. Med. Bull. 62(1), 45-58 (2002). Proof in principle of the utility of genomics for vaccine discovery.
15. Hoiseth S. Vaccines, Bacterial. In: Encyclopedia of Microbiology. Lederberg J (Ed.). Academic Press, 767-778 (2000).
16. Cripps AW, Foxwell R, Kyd J. Challenges for the development of vaccines against Haemophilus influenzae and Neisseria meningitidis. Curr. Opin. Immunol. 14(5), 553-557 (2002).
17. Rubin EJ. Bacterial genomics and vaccine design. Expert Rev. Vaccines 2(3), 437-445 (2003).
18. Grandi G. Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol. 19(5), 181-188 (2001). Good review on the application of genomic technologies in vaccine discovery.
19. Zagursky RJ, Russell D. Bioinformatics: Use in Bacterial Vaccine Discovery. In: BioComputing: Computer Tools for Biologists. Brown SM (Ed.), Eaton Publishing, 261-285 (2003). Comprehensive review of genomic algorithms being applied for bacterial vaccine discovery.
20. Alm RA, Ling LS, Moir DT et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397(6715), 176-180 (1999). Published erratum appears in Nature 397(6721), 719 (1999).
21. Blattner FR, Plunkett G 3rd, Bloch CA et al. The complete genome sequence of Escherichia coli K-12. Science 277(5331), 1453-1474 (1997).
22. Inamine JM, Ho KC, Loechel S, Hu PC. Evidence that UGA is read as a tryptophan codon rather than as a stop codon by Mycoplasma pneumoniae, Mycoplasma genitalium and Mycoplasma gallisepticum. J. Bacteriol. 172(1), 504-506 (1990).
23. Liu Z, Reches M, Groisman I, EngelbergKulka H. The nature of the minimal 'selenocysteine insertion sequence' (SECIS) in Escherichia coli. Nucleic Acids Res. 26(4), 896-902 (1998).
24. Delcher AL, Harmon D, Kasif S, White O, Salzberg SL. Improved microbial gene identification with GLIMMER. Nucleic Acids Res. 27(23), 4636-4641 (1999).
25. Ramakrishna R, Srinivasan R. Gene identification in bacterial and organellar genomes using GeneScan. Computers Chemistry 23(2), 165-174 (1999).
26. von Heijne G. Signal sequences. The limits of variation. J. Mol. Biol. 184(1), 99-105 (1985).
27. Shine J, Dalgarno L. The 3′-terminal sequence of Escherichia coli 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding sites. Proc Natl Acad. Sci. USA 71(4), 1342-1346 (1974).
28. Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148(10), 2967-2973 (2002).
29. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Int. J. Neural Syst. 8(5-6), 581-599 (1997).
30. von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res. 14(11), 4683-4690 (1986).
31. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 10(1), 1-6 (1997).
32. Nielsen H, Brunak S, von Heijne G. Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Protein Eng. 12(1), 3-9(1999).
33. Cabanes D, Dehoux P, Dussurget O, Frangeul L, Cossart P. Surface proteins and the pathogenic potential of Listeria monocytogenes. Trends Microbiol. 10(5), 238-245 (2002).
34. Reinhardt A, Hubbard T. Using neural networks for prediction of the subcellular location of proteins. Nucleic Acids Res. 26(9), 2230-2236 (1998).
35. Cedano J, Aloy P, Perez-Pons JA, Querol E. Relation between amino acid composition and cellular location of proteins. J. Mol. Biol. 266(3), 594-600 (1997).
36. Nakai K, Kanehisa M. Expert system for predicting protein localization sites in Gram-negative bacteria. Proteins 11(2), 95-110 (1991).
37. Nakai K, Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem. Sci. 24(1), 34-36 (1999).
38. Nakai K. Protein sorting signals and prediction of subcellular localization. Adv. Protein Chem. 54, 277-344 (2000).
39. Eisenberg D, Schwarz E, Komaromy M, Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 179(1), 125-142 (1984).
40. Lio P, Vannucci M. Wavelet change-point prediction of transmembrane proteins. Bioinformatics 16(4), 376-382 (2000).
41. Gromiha MM, Majumdar R, Ponnuswamy PK. Identification of membrane spanning β-strands in bacterial porins. Protein Eng. 10(5), 497-500 (1997).
42. Cserzo M, Wallin E, Simon I, von Heijne G, Elofsson A. Prediction of transmembrane α-helices in prokaryotic membrane proteins: the dense alignment surface method. Protein Eng. 10(6), 673-676 (1997).
43. Claros MG, von Heijne G. TopPred II: an improved software for membrane protein structure predictions. Comput. Appl. Biosci. 10(6), 685-686 (1994).
44. van Belkum A, Scherer S, van Alphen L, Verbrugh H. Short-sequence DNA repeats in prokaryotic genomes. Microbiol. Mol. Biol. Rev. (Washington, DC) 62(2), 275-293 (1998).
45. Moxon ER, Rainey PB, Nowak MA, Lenski RE. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr. Biol. 4(1), 24-33 (1994).
46. Saunders NJ, Peden JF, Hood DW, Moxon ER. Simple sequence repeats in the Helicobacter pylori genome. Mol. Microbiol. 27(6), 1091-1098 (1998).
47. Saunders NJ, Jeffries AC, Peden JF et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol. Microbiol. 37(1), 207-215 (2000).
48. Benson G. Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acid Res. 27(2), 573-580 (1999).
49. Persson B. Bioinformatics in protein analysis. In: Proteomics in Functional Genomics: Protein Structure Analysis. Jolles P and Jornvall H (Eds). Birkhauser, Basel, Switzerland, 215-231 (2000).
50. Zhai Y, Saier MH, Jr. The β-barrel finder (BBF) program, allowing identification of outer membrane β-barrel proteins encoded within prokaryotic genomes. Protein Sci. 11(9), 2196-2207 (2002).
51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J. Mol. Biol. 215(3), 403-410 (1990).
52. Henikoff JG, Greene EA, Pietrokovski S, Henikoff S. Increased coverage of protein families with the blocks database servers. Nucleic Acids Res. 28(1), 228-230 (2000).
53. Bateman A, Birney E, Durbin R et al. The Pfam protein families database. Nucleic Acids Res. 28(1), 263-266 (2000).
54. Hofmann K, Bucher P, Falquet L, Bairoch A. The PROSITE database, its status in 1999. Nucleic Acids Res. 27(1), 215-219 (1999).
55. Doytchinova IA, Flower DR. Quantitative approaches to computational vaccinology. Immunol Cell Biol. 80(3), 270-279 (2002).
56. De Groot AS, Bosma A, Chinai N et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19(31), 4385-4395 (2001).
57. Sassetti C, Rubin EJ. Genomic analyses of microbial virulence. Curr. Opin. Microbiol. 5(1), 27-32 (2002).
58. Ariel N, Zvi A, Grosfeld H et al. Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect. Immun. 70(12), 6817-6827 (2002).
59. Cole ST. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 148(Part 10), 2919-2928 (2002).
60. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol. Microbiol. 45(6),1499-1513 (2002).
61. Alm RA, Ling LSL, Moir DT et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397(6721), 719 (1999).
62. Kalman S, Mitchell W, Marathe R et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. 21(4), 385-389 (1999).
63. Bruccoleri RE, Dougherty TJ, Davison DB. Concordance analysis of microbial genomes. Nucleic Acids Research. 26(19), 4482-4486 (1998).
64. Smoot JC, Barbian KD, Van Gompel JJ et al. Genome sequence and comparative microarray analysis of serotype M 18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc. Natl Acad. Sci. USA 99(7), 4668-4673 (2002).
65. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4), 533-537 (1997).
66. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat. Genet. 21(Suppl. 1), 48-50 (1999).
67. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cellular Biol. 19(3), 1720-1730 (1999).
68. Wilkins MR, Sanchez JC, Williams KL, Hochstrasser DF. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 17(5), 830-838 (1996).
69. Cordwell SJ, Nouwens AS, Walsh BJ. Comparative proteomics of bacterial pathogens. Proteomics 1(4), 461-472 (2001).
70. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 66(1), 39-63 (2002). A great technical review of the field of proteomics.
71. Henzel WJ, Billeci TM, Stults JT et al. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc. Natl Acad. Sci. USA 90(11), 5011-5015 (1993).
72. Chakravarti DN, Chakravarti B, Moutsatsos I. Informatic tools for proteome profiling. Biotechniques (Suppl. 4-10), 12-15 (2002).
73. Smith RD, Anderson GA, Lipton MS et al. An accurate mass tag strategy for quantitative and high-throughput proteome measurements. Proteomics 2(5), 513-523 (2002). This study demonstrates that highly complex peptide mixtures can be deconvoluted with very high mass accuracy and efficient LC separation.
74. Lipton MS, Pasa-Tolic L, Anderson GA et al. Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc. Natl Acad. Sci. USA 99(17), 11049-11054 (2002).
75. Lay JO. MALDI-TOF mass spectrometry of bacteria. Mass Spectrom. Rev. 20(4), 172-194 (2001). Description of the general use of MALDI-TOF MS for the identification of bacterial proteins.
76. Regula JT, Ueberle B, Boguth G et al. Towards a two-dimensional proteome map of Mycoplasma pneumoniae. Electrophoresis 21(17), 3765-3780 (2000).
77. Vuong GL, Weiss SM, Kammer W et al. Improved sensitivity proteomics by postharvest alkylation and radioactive labeling of proteins. Electrophoresis 21(13), 2594-2605 (2000).
78. Wasinger VC, Pollack JD, HumpherySmith I. The proteome of Mycoplasma genitalium. Chaps-soluble component. Eur. J. Biochem. 267(6), 1571-1582 (2000).
79. Issaq HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 23(17), 3048-3061 (2002).
80. Rylatt DB, Napoli M, Ogle D et al. Electrophoretic transfer of proteins across polyacrylamide membranes. J. Chromatogr. 865(1-2), 145-153 (1999).
81. Nilsson CL, Larsson T, Gustafsson E, Karlsson KA, Davidsson P. Identification of protein vaccine candidates from Helicobacter pylori using a preparative twodimensional electrophoretic procedure and mass spectrometry. Anal. Chem. 72(9), 2148-2153 (2000).
82. Haas G, Karaali G, Ebermayer K et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2(3), 313-324 (2002). This study is a tour deforce in mapping the immune response to several hundred bacterial proteins in relation to clinical severity of disease.
83. Svensater G, Welin J, Wilkins JC, Beighton D, Hamilton IR. Protein expression by planktonic and biofilm cells of Streptococcus mutans. FEMS Microbiol. Lett. 205(1), 139-146 (2001). An excellent example of the use of 2D gel electrophoresis in combination with MALDI-TOF MS.
84. Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S. α-Enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol. Microbiol. 40(6), 1273-1287 (2001).
85. Lei B, Mackie S, Lukomski S, Musser JM. Identification and immunogenicity of group A Streptococcus culture supernatant proteins. Infect. Immun. 68(12), 6807-6818. (2000). A preliminary study using proteomics to identify novel proteins of S. pyogenes.
86. Hughes MJ, Moore JC, Lane JD et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect. Immun. 70(3), 1254-1259 (2002).
87. Freiberg C, Brunner NA Genome-wide mRNA profiling: impact on compound evaluation and target identification in antibacterial research. Targets 1(1), 20-29 (2002).
88. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 303, 179-205 (1999).
89. Rauhut R, Klug G. mRNA degradation in bacteria. FEMS Microbiology Reviews. 23(3), 353-370 (1999).
90. Bemstein JA, Khodursky AB, Lin P-H, LinChao S, Cohen SN. Global analysis of mRNA decay and abundance in Escherichia coli at single-gene resolution using two-color fluorescent DNA microarrays. Proc. Natl Acad. Sci. USA 99(15), 9697-9702 (2002).
91. Cummings CA, Relman DA. Using DNA microarrays to study host-microbe interactions. Emerg. Infect. Dis. 6(5), 513-525 (2000).
92. Relman DA. Genome-wide responses of a pathogenic bacterium to its host. J. Clin. Invest. 110(8), 1071-1073 (2002).
93. Ang S, Lee CZ, Peck K et al. Acid-induced gene expression in Helicobacter pylori: Study in genomic scale by microarray Infect. Immun. 69(3), 1679-1686 (2001).
94. Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413(6858), 860-864 (2001).
95. Schoolnik GK. Functional and comparative genomics of pathogenic bacteria. Curr. Opin. Microbiol. 5(1), 20-26 (2002).
96. Tjaden B, Saxena RM, Stolyar S et al. Transcriptome analysis of Escherichia coli using high-density oligonucleotide probe arrays. Nucleic Acids Res. 30(17), 3732-3738 (2002).
97. Goerke C, Campana S, Bayer MG et al. Direct quantitative transcript analysis of the agr regulon of Staphylococcus aureus during human infection in comparison to the expression profile in vitro. Infect. Immun. 68(3), 1304-1311 (2000).
98. Merrell DS, Butler SM, Qadri F et al. Host-induced epidemic spread of the cholera bacterium. Nature 417(6889), 642-645 (2002). First report of transcriptional profiling of V. cholerae from human stool samples.
99. Betts JC. Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis. IUBMB Life 53(4-5), 239-242 (2002).
100. Rathod PK, Ganesan K, Hayward RE, Bozdech Z, DeRisi JL. DNA microarrays for malaria. Trends Parasitol. 18(1), 39-45 (2002).
101. McClelland M, Sanderson KE, Spieth J et al. Complete genome sequence of Salmonella enterica serovar typhimurium LT2. Nature 413(6858), 852-856 (2001).
102. Grifantini R, Bartolini E, Muzzi A et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol. 20(9), 914-921 (2002). Excellent report demonstrating the identification of novel vaccine targets using DNA microarrays and how it complements other genomic methods used for vaccine discovery.
103. Chiang SL, Mekalanos JJ, Holden DW. In vivo genetic analysis of bacterial virulence. Ann. Rev. Microbiol. 53(1), 129-154 (1999).
104. Merrell DS, Camilli A. Detection and analysis of gene expression during infection by in vivo expression technology. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 355(1397), 587-599 (2000).
105. Mecsas J. Use of signature-tagged mutagenesis in pathogenesis studies. Curr. Opin. Microbiol. 5(1), 33-37 (2002).
106. Sun Y-H, Bakshi S, Chalmers R, Tang CM. Functional genomics of Neisseria meningitidis pathogenesis. Nature Med. 6(11), 1269-1273 (2000).
107. Joloba ML, Windau A, Bajaksouzian S et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin. Infect. Dis. 33(9), 1489-1494 (2001).
108. Peters TR, Edwards KM. Pneumococcal vaccines: present and future. Pediatr. Ann. 31(4), 261-268 (2002).
109. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect Dis. J. 19(3), 187-195 (2000).
110. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810-815 (2002).
111. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med 344(6), 403-409 (2001).
112. Tettelin H, Nelson KE, Paulsen IT et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293(5529), 498-506 (2001).
113. Hoskins J, Albom WE, Arnold J et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183(19), 5709-5717 (2001).
114. Wizemann TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69(3), 1593-1598 (2001).
115. Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69(2), 949-958 (2001).
116. Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol. Microbiol. 45(5), 1389-1406 (2002).
117. Lau GW, Haataja S, Lonetto M et al. A functional genomic analysis of Type 3 Streptococcus pneumoniae virulence. Mol. Microbiol. 40(3), 555-571 (2001).
118. O'Brien KL, Beall B, Barrett NL et al. Epidemiology of invasive Group A Streptococcus disease in the United States, 1995-1999. Clin. Infect. Dis. 35(3), 268-276 (2002).
119. Ferretti JJ, McShan WM, Ajdic D et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc. Acad. Sci. USA 98(8), 4658-4663 (2001).
120. Beres SB, Sylva GL, Barbian KD et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype and clone emergence. Proc. Natl Acad. Sci. USA 99(15), 10078-10083 (2002).
121. Medaglini D, Pozzi G, King TP, Fischetti VA. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl Acad. Sci. USA 92(15), 6868-6872 (1995).
122. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B-cell epitope and lacks a T-cell autoepitope. Vaccine 20(21-22), 2816-2825 (2002).
123. Hu MC, Walls MA, Stroop SD et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect. Immun. 70(4), 2171-2177 (2002).
124. Cywes C, Wessels MP. Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature 414(6864), 648-652 (2001).
125. Cunningham MW, Quinn A. Immunological crossreactivity between the class I epitope of streptococcal M protein and myosin. Adv. Exp. Med. Biol. 418, 887-892 (1997).
126. Cunningham MW. Pathogenesis of Group A streptococcal infections. Clin. Microbiol. Rev. 13(3), 470-511 (2000). An excellent review to gain an overall understanding of S. pyogenes pathogenesis and virulence.
127. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect. Immun. 69(6), 4072-4078 (2001).
128. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus. Infect. Immun. 65(6), 2080-2087 (1997).
129. Reid SD, Green NM, Buss JK, Lei B, Musser JM. Multilocus analysis of extracellular putative virulence proteins made by Group A Streptococcus: population genetics, human serologic response and gene transcription. Proc. Natl Acad. Sci. USA 98(13), 7552-7557 (2001).
130. Reid SD, Green NM, Sylva GL et al. Postgenomic analysis of four novel antigens of group A Streptococcus: Growth phasedependent gene transcription and human serologic response. J. Bacteriol. 184(22), 6316-6324 (2002).
131. Ginsberg AM. What's new in tuberculosis vaccines? Bull. World Health Organ. 80(6), 483-488 (2002).
132. Salyers AA, Whitt DD. Tuberculosis. In: Bacterial Pathogenesis: a Molecular Approach. Salyers AA, Whitt DD (Eds). ASM Press, 307-321 (2002).
133. Kaufmann SHE, Hess J. Immune response against Mycobacterium tuberculosis: implications for vaccine development. J. Biotechnol. 83(1-2), 13-17 (2000).
134. Munoz-Elias EJ, McKinney JD. Bacterial persistence: strategies for survival. In: Immunology of Infectious Diseases. Kaufmann SHE, Sher A, Ahmed A (Eds), ASM Press, 331-355 (2002).
135. Behr MA. BCG - different strains, different vaccines? Lancet Infect. Dis. 2(2), 86-92 (2002).
136. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346(8986), 1339-1345 (1995).
137. Mustafa AS. Development of new vaccines and diagnostic reagents against tuberculosis. Mol. Immunol. 39(1-2), 113-119 (2002).
138. Horwitz MA, Harth G, Dillon BJ, MaslesaGalić S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97(25), 13853-13858 (2000).
139. Wang JT, Xing Z. Tuberculosis vaccines: the past, present and future. Expert Rev. Vaccines 1(3), 341-354 (2002).
140. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberadosis from the complete genome sequence. Nature 396(6707), 190-198 (1998).
141. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184(19), 5479-5490 (2002).
142. Kato-Maeda M, Rhee JT, Gingeras TR et al. Comparing genomes within the species Mycobacterium tuberculosis. Genome Res. 11 (4), 547-554 (2001).
143. Mattow J, Jungblut PR, Schaible UE et al. Identification of proteins from Mycobacterium tuberculosis missing in attenuated Mycobacterium bovis BCG strains. Electrophoresh 22(14), 2936-2946 (2001).
144. Cole ST. Comparative mycobacterial genomics as a tool for drug target and antigen discovery. Eur. Respir. J. 20(Suppl. 36), 78S-86S (2002).
145. Gomez M, Johnson S, Gennaro ML. Identification of secreted proteins of Mycobacterium tuberculosis by a bioinformatic approach. Infect. Immun. 68(4), 2323-2327 (2000).
146. Rosenkrands I, King A, Weldingh K et al. Towards the proteome of Mycobacterium tuberculosis. Electrophoresis 21(17), 3740-3756 (2000).
147. Rosenkrands I, Slayden RA, Crawford J et al. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J. Bacteriol. 184(13), 3485-3491 (2002).
148. Fisher MA, Plikaytis BB, Shinnick TM. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J. Bacteriol. 184(14), 4025-4032 (2002).
149. Covert BA, Spencer JS, Orme IM, Belisle JT. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomics 1(4), 574-586 (2001).
150. + T-cells. J. Exp. Med. 191(3), 551-560 (2000).
151. Flyer DC, Ramakrishna V, Miller C et al. Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect. Immun. 70(6), 2926-2932 (2002). Very good demonstration of how mass spectrometry can be used to identify MHC T cell epitopes.
152. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S114-S132 (2001).
153. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72(2), 195-198 (1992).
154. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51(26), 565-567 (2002).
155. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin. Microbiol. Rev. 15(3), 430-438 (2002).
156. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 27(5), 887-892 (1999).
157. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 13(1), 16-34 (2000).
158. Orwin PM, Leung DY, Tripp TJ et al. Characterization of a novel staphylococcal enterotoxin-like superantigen, a member of the group V subfamily of pyrogenic toxins. Biochemistry (Mosc). 41(47), 14033-14040 (2002).
159. Leung DY, Meissner HC, Shulman ST et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J. Pediatr. 140(6), 742-746 (2002).
160. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346(7), 491-496 (2002).
161. Norcross NL. Immune response of the mammary gland and role of immunization in mastitis control. J. Am. Vet. Med. Assoc. 170(10 Pt 2), 1228-1233 (1977).
162. Williams JM, Mayerhofer HJ, Brown RW. Clinical evaluation of a Staphylococcus aureus bacterin (polyvalent somatic antigen). Vet. Med. Small Anim. Clin. 61(8), 789-793 (1966).
163. O'Brien CN, Guidry AJ, Fattom A et al. Production of antibodies to Staphylococcus aureus serotypes 5, 8 and 336 using poly(DLlactide-co-glycolide) microspheres. J. Dairy Sci. 83(8), 1758-1766 (2000).
164. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6(12), 484-488 (1998).
165. Joh D, Wann ER, Kreikemeyer B, Speziale P, Hook M. Role of fibronectin-binding MSCRAMMs in bacterial adherence and entry into mammalian cells. Matrix Biol. 18(3), 211-223 (1999).
166. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359(9320), 1819-1827 (2002).
167. Kuroda M, Ohta T, Uchiyama I et al. Whole genome sequencing of meticillinresistant Staphylococcus aureus. Lancet 357(9264), 1225-1240 (2001).
168. Yarwood JM, McCormick JK, Paustian ML et al. Characterization and expression analysis of Staphylococcus aureus pathogenicity island 3. Implications for the evolution of staphylococcal pathogenicity islands. J. Biol. Chem. 277(15), 13138-13147 (2002).
169. Fitzgerald JR, Sturdevant DE, Mackie SM, Gill SR, Musser JM. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillinresistant strains and the toxic shock syndrome epidemic. Proc. Natl Acad. Sci. USA 98(15), 8821-8826 (2001).
170. Vytvytska O, Nagy E, Bluggel M et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2(5), 580-590 (2002). An excellent study and application of 2D gel electrophoresis and MALDITOF MS in combination with human convalescent sera to identify immunoreactive proteins of S. aureus.
171. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99(10), 6573-6578 (2002). A preliminary study to identify in vivo expressed S. aureus genes through the use of a peptide library.
172. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 20(5-6), 666-687 (2002).
173. Devi S, Zollinger W, Snoy P et al. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. 65(3), 1045-1052 (1997).
174. Pon RA, Lussier M, Yang Q-L, Jennings HJ. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 185(11), 1929-1938 (1997).
175. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 359(9316), 1499-1508 (2002).
176. Bethell D, Pollard AJ. Meningococcal vaccines. Expert Rev. Vaccines 1(1), 75-84 (2002).
177. Parkhill J, Achtman M, James KD et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404(6777), 502-506 (2000).
178. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459), 1809-1815 (2000).
179. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000). First paper to describe using genomic mining and the subsequent immunoassays toward the identification of vaccine targets against N. meningitidis.
180. Granoff DM, Moe GR, Giuliani MA et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J. Immunol. 167(11), 6487-6496 (2001).
181. Poolman J, Berthet FX. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 20(Suppl. 1), S24-S26 (2001).
182. Perrin A, Bonacorsi S, Carbonnelle E et al. Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other neisseria species. Infect. Immun. 70(12), 7063-7072 (2002).
183. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ. Genomics in anti-infective drug discovery - getting to endgame. Curr. Pharm. Des. 8(13), 1099-1118 (2002).
184. Huels C, Muellner S, Meyer HE, Cahill DJ. The impact of protein biochips and microarrays on the drug development process. Drug Discov. Today 7(18 Suppl.), S119-S124 (2002).
185. Eickhoff H, Konthur Z, Lueking A et al. Protein array technology: the tool to bridge genomics and proteomics. Adv. Biochem. Eng. Biotechnol. 77, 103-112 (2002).
186. Templin MF, Stoll D, Schrenk M et al. Protein microarray technology. Trends Biotechnol. 20(4), 160-166 (2002).
187. Guttmacher AE, Collins FS. Genomic medicine - a primer. N. Engl. J. Med. 347(19), 1512-1520 (2002).